News

MedPage Today on MSN1d
FDA Lifts Pause on Chikungunya Vaccine in Older Adults, With Revised Labeling
"Based on the available data, and its benefit-risk assessment, FDA has removed the recommended pause in the use of Ixchiq in ...
Becker's Hospital Review4h
FDA lifts pause on Chikungunya vaccine use in adults 60 and older
The FDA has lifted its previously recommended pause on the use of the Chikungunya virus vaccine in individuals 60 and older, following a benefit-risk assessment. The agency also approved updated ...
FDA lifts pause on Valneva’s chikungunya shot, but adds new limits
The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...
MPR1d
FDA Lifts Valneva’s Chikungunya Vaccine Use Restriction in Older Adults
As part of a postmarketing requirement, Valneva will be initiating a study to assess the risk of severe chikungunya-like adverse reactions following administration of Ixchiq.
FDA lifts pause on Valneva's chikungunya vaccine in elderly
Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...
MedPage Today on MSN4d
Did FDA Pick the Wrong COVID Vaccine Strain Last Season?
A separate Danish study showed that the two mRNA vaccines were also safe, with no increase in adverse events of special ...
US FDA's top vaccine official Vinay Prasad leaves agency after 3 months
The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as ...
Top FDA vaccine regulator abruptly exits post
DIRECTING A CHANGING CDC — The Senate voted to confirm Susan Monarez as the next CDC director Tuesday, marking an end to the ...
FDA vaccine chief leaving agency after less than 3 months
Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure.
PharmExec2d
HHS Announces Reduction in mRNA Vaccine Development Programs Under BARDA, Nearly $500 Million in Contracts Cancelled
Overall, the initial steps of the wind-down will result the in the cancellation of nearly $500 million. Not all mRNA related ...